ViVac Pharma Appoints Keren Leshem as New CEO
ViVac Pharma Ltd., a pioneering name in synthetic biology focused on advancing RNA–Lipid Nanoparticle (LNP) immunotherapies, is excited to announce the appointment of Keren Leshem as its new Chief Executive Officer. This strategic move comes as the company seeks to enhance its leadership to further its innovative approach in the biotechnology sector.
Keren Leshem: A Visionary Leader
Keren Leshem is highly regarded in the industry, having received recognition from prestigious platforms such as Forbes and Entrepreneur as one of the most influential leaders in life sciences. With nearly three decades of experience, she has a proven track record in guiding clinical-stage life science companies and transforming groundbreaking research into commercial successes.
Empowering the Oncology Pipeline
Under Leshem's guidance, ViVac is poised to accelerate its preclinical oncology pipeline, focusing on significant unmet needs in treating liver, ovarian, and various solid tumors. These programs are essential for addressing tumors that show resistance to conventional treatment methods, showcasing the company’s commitment to tackling cancer head-on.
A Transformative Approach to Cancer Treatment
"ViVac's science represents a paradigm shift in oncology — utilizing synthetic RNA to emulate the power of viral immunity, while ensuring the safety and control associated with advanced nanomedicine," said Keren Leshem. Leading a world-class team of scientists and investors, she is eager to cultivate the next wave of RNA-based cancer immun therapies.
Innovators Behind ViVac Pharma
ViVac's leadership team is equipped with renowned experts. Dr. Lior Nissim heads the Biomedical Synthetic Biology Lab and is known for pioneering the first synthetic gene circuit designed for precise cancer cell targeting. Additionally, Prof. Chezy Barenholz, a leading figure in liposome technology, is recognized globally for his contributions to nanomedicine, including co-inventing Doxil — the first FDA-approved liposomal nanodrug. Dr. Ron Lahav, the Chief Technology Officer, specializes in RNA delivery systems that enhance the company’s innovative capabilities.
Support from Influential Investors
ViVac is backed by highly regarded investors in the life sciences realm, including Dr. Jean de Gunzburg and Tuomas Tenkanen, both of whom bring substantial experience in biotech innovation, mergers and acquisitions, and global commercialization strategies. Their expertise will support ViVac in its ambitious goals.
Future Outlook in Cancer Immunotherapy
The global cancer immunotherapy landscape is expected to surpass $125 billion by 2032, propelled by the increasing adoption of next-generation RNA-based methodologies. ViVac's modular RNA–LNP platform is designed for scalability, facilitating rapid expansion into various oncology applications.
About ViVac Pharma Ltd.
ViVac is an innovative early-stage biotechnology enterprise specializing in synthetic biology and lipid nanoparticle engineering to develop RNA-driven immunotherapies that aim to eliminate cancer safely. Founded from two leading research labs at the Hebrew University of Jerusalem, ViVac's unique platform effectively reprograms RNA to mimic viral behavior, enhancing localized immune responses without the risks associated with viral replication.
Frequently Asked Questions
What is ViVac Pharma known for?
ViVac Pharma Ltd. specializes in developing RNA–Lipid Nanoparticle immunotherapies aimed at treating cancers through synthetic biology.
Who is the new CEO of ViVac Pharma?
Keren Leshem has been appointed as the Chief Executive Officer, bringing extensive experience in the life sciences sector.
What innovations is ViVac focusing on?
ViVac is enhancing its oncology pipeline, specifically targeting liver, ovarian, and resistant solid tumors using novel RNA-based strategies.
Who are the key members of ViVac's leadership team?
Key members include Dr. Lior Nissim, Prof. Chezy Barenholz, and Dr. Ron Lahav, who contribute substantial expertise in synthetic biology and RNA delivery.
What is the market outlook for cancer immunotherapy?
The cancer immunotherapy market is forecasted to grow significantly, potentially exceeding $125 billion by the year 2032, driven by next-gen RNA approaches.
